Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

NEW YORK & MIAMI, July 10, 2018 — A Parkinson’s Foundation study recently published in the scientific journal, npj Parkinson’s Disease, reveals findings from the most comprehensive estimate of Parkinson’s disease in the United States and Canada to date. The Foundation’s “Parkinson’s Prevalence Project” estimates that 930,000 people in the United States will be living with the disease by 2020, further increasing to 1.2 million people by 2030.

"Our knowledge of Parkinson’s has evolved significantly and so should our understanding of the population that has this disease,” said James Beck, PhD, Parkinson’s Foundation Chief Scientific Officer and contributing author on the study. “These findings will help attract the attention of federal and state government as well as the pharmaceutical industry to the growing need and urgency in addressing Parkinson’s disease.”

The Parkinson’s Foundation formed the “Parkinson’s Prevalence Project” in 2014 to determine an updated estimate of the prevalence of Parkinson’s throughout North America. Prior estimates were deemed outdated and based on a small number of cases from small regional subpopulations – such as a study performed in a rural Mississippi county finding 26 cases was long used as the benchmark estimate for Parkinson’s prevalence in the US. The Parkinson’s Prevalence Project revised estimate draws from larger and more diverse populations and is almost double the previous estimate:

  • The research combined data from a multi-study sampling strategy in diverse geographic regions including California, Minnesota, Hawaii, and Ontario, Canada and compared those results to U.S. Medicare data.
  • The estimated overall prevalence of Parkinson’s among those 45 years old or older is 572 per 100,000, which translates into 680,000 individuals in the U.S. who are at least 45 years old with Parkinson’s in 2010, the date of the last official U.S. census.
  • The prevalence of Parkinson’s will rise to approximately 930,000 in 2020 and 1,238,000 in 2030 based on the U.S. Census Bureau population projections.

Connie Marras, MD, PhD, lead author on the study and movement disorder neurologist at the Movement Disorders Centre at Toronto Western Hospital, a Parkinson’s Foundation Center of Excellence and the Edmond J. Safra Program in Parkinson’s research said, “Like Alzheimer’s disease, Parkinson’s affects primarily older individuals and poses a significant health care burden, as well as a real challenge on how to care for the aging population over the coming decades.”

Added John L. Lehr, CEO of the Parkinson’s Foundation: “One million Americans living with Parkinson’s by 2020 highlights the growing importance of optimizing care and treatment for people with the disease today. We continue to support scientific research, including through our ‘Parkinson’s Outcomes Project,’ the largest clinical study of Parkinson’s in the world, to help better understand what causes the disease, how to treat it and potentially stop progression and improve the lives of everyone living with the disease.”

Later this year, the Parkinson’s Foundation will be leading phase two of the prevalence study to better understand, on a national scale, how many people are diagnosed each year with Parkinson’s as well as the rate of mortality of people with the disease.

For more information about Parkinson’s statistics, visit Parkinson.org/Statistics.

###

About the Parkinson’s Foundation 
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. For more information, visit www.parkinson.org or call (800) 4PD-INFO (473-4636).

About Parkinson’s Disease 
Affecting nearly one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

 

Tuesday, July 10, 2018
Parkinson’s Foundation Elects Howard D. Morgan Chairman of the Board
Tuesday, June 26, 2018

MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.

Parkinson’s Foundation Announces Five New Members of its People with Parkinson’s Advisory Council
Wednesday, June 13, 2018

NEW YORK & MIAMI — June 13, 2018 — The Parkinson’s Foundation today announced five new members of its People with Parkinson’s Advisory Council.

The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Delegates From The Parkinson’s Community Converge On Capitol Hill To Advocate For Critical Research Funding
Monday, March 5, 2018

—2018 Parkinson’s Policy Forum Co-Sponsored by the Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research—

Parkinson’s Foundation Appoints Jena E. Abernathy to Board of Directors
Tuesday, February 27, 2018

MIAMI – February 27, 2018 –  The Parkinson’s Foundation today announced the election of Jena E. Abernathy to its board of directors.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.